SPRYCEL 140 MG
DASATINIB (DASATINIB MONOHYDRATE) : 140 MG · DIN 02360829 · BRISTOL-MYERS SQUIBB CANADA
Health Canada status: MARKETED
What is SPRYCEL?
SPRYCEL 140 MG contains DASATINIB (DASATINIB MONOHYDRATE) : 140 MG. It is listed in the Health Canada Drug Product Database under DIN 02360829, held by BRISTOL-MYERS SQUIBB CANADA, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 29-Mar-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SPRYCEL used for?
Newly diagnosed Ph+ CML in chronic phase; Ph+ CML (chronic, accelerated, or blast phase) with resistance/intolerance to prior therapy; Ph+ ALL with resistance/intolerance to prior therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02360829 |
|---|---|
| Brand name | SPRYCEL |
| Generic / active ingredient | DASATINIB (DASATINIB MONOHYDRATE) : 140 MG |
| Manufacturer | BRISTOL-MYERS SQUIBB CANADA |
| Strength | 140 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01EA02 DASATINIB |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Mar-2011 |
| Original market date | 2011-03-29 00:00:00 |
How is it administered?
Chronic phase CML: 100 mg once daily. Advanced phase CML or Ph+ ALL: 140 mg once daily. Administer orally, morning or evening. Tablets must be swallowed whole.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. (Note: General storage section referenced in TOC, specific conditions typically 15-30°C for this product).
How is it supplied?
20, 50, 70 mg: HDPE bottles or blister packs of 60 tablets. 80, 100, 140 mg: HDPE bottles or blister packs of 30 tablets.
Contraindications
Breastfeeding; hypersensitivity to dasatinib or any component of the formulation.
Warnings and precautions
Serious: Myelosuppression, hemorrhage (including fatal), fluid retention (pleural effusion, pulmonary edema), congestive heart failure, pulmonary arterial hypertension, HBV reactivation.
What can be used instead?
Other Canadian products sharing ATC code L01EA02 DASATINIB. 28 of 28 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-DASATINIB | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02470721 |
| APO-DASATINIB | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02470705 |
| APO-DASATINIB | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02470713 |
| APO-DASATINIB | 70 MG | TABLET | APOTEX INC | MARKETED | DIN 02481499 |
| APO-DASATINIB | 80 MG | TABLET | APOTEX INC | MARKETED | DIN 02481502 |
| REDDY-DASATINIB | 100 MG | TABLET | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02514788 |
| REDDY-DASATINIB | 140 MG | TABLET | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02514796 |
| REDDY-DASATINIB | 20 MG | TABLET | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02514737 |
| REDDY-DASATINIB | 50 MG | TABLET | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02514745 |
| REDDY-DASATINIB | 70 MG | TABLET | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02514753 |
Who else supplies DASATINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DASATINIB appears in 1588 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.